Dexmedetomidine to reduce anesthetic requirements during heart surgery;Dexmedetomidina para disminuir requerimientos anestésicos en pacientes sometidos a cirugía cardíaca con derivación cardiopulmonar

Revista Mexicana de Anestesiologia

Volumn 29, Issue 1, 2006, Pages 20-25

  Briones Corona, Gabriela ^a,b   Moreno Alatorre, Marco Antonio ^a   Lozano Noriega, Roberto ^a  

^a HOSPITAL DE CARDIOLOGÍA   (Mexico)

^b Hospital de Cardiología CMN Siglo XXI   (Mexico)

Author keywords

Cardiopulmonary bypass; Dexmedetomidine; Fentanyl mean rate; Halogenated percent volume; Heart surgery; Inotropics

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; ISOFLURANE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; FEMALE; HEART RATE; HEART SURGERY; HUMAN; INOTROPISM; MAINTENANCE DRUG DOSE; MALE; SCHOOL CHILD;

EID: 33646261426     PISSN: 01851012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hensley F, Martín ED, Gravlee G. Anestesia cardíaca. Editorial Marbán Tercera Edición 2004:281-284.
2. th Edition. Editorial Harcout Brace. 1999;Tomo II:699-701.
3. Luna P. Anestesia cardiovascular. Segunda edición. Editorial McGraw-Hill Interamericana. 1997:158-163.
4. Jouko J, Markky H, Anne K, et al. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology 1997;56:331-345.
5. Takahiko K, Mervyn M. Clinical uses of α - adrenergic agonist. Anesthesiology 2000;93:1345-1349.
6. Hogue C, Talke P, Stein P, et al. Autonomic nervous system responses during sedative infusions of dexmedetomidine. Anesthesiology 2002;97:592-598.
7. Talke P, Jain U, Leung J, et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. Anesthesiology 1995;82:620-633.
8. Aantaa R. Assessment of the sedative effects of dexmedetomidine, an a2-adrenergic agonist, with analysis pos saccadic eye movements. Pharmacol Toxicol 1991;68:394-398.
9. Aantaa R, Kallio A, Virtanen R. Dexmedetomidine, a novel alpha 2-adrenergic agonist. A review of its pharmacodynamic characteristics. Drug of the Future 1993;18(1):49-56.
10. Dyck JB, Shafer SL. Dexmedetomidine pharmacokinetics and pharmacodynamics. Anaesth Pharm Review 1993;1:238-245.
11. Maze M. Clinical Uses of a2-agonist. In: Barash PG, ed. The American Society of Anesthesiologist Philadelphia. Lippincott JB 1992;20:133-142.
12. Kornfeld DS. Psychiatric problems of an intensive care unit. Med Clin North Am 1971;55:1353-1363.
13. Maze M. Sedation in the intensive care unit. International Congress and Symposium Series Redefining Sedation 1998;221:3-10.
14. Aantaa R, Kanto J, Scheinin, et al. Dexmedetomidine, an a2-adrenoceptor agonist, reduces anaesthetic requirements for patients undergoing minor gynecological surgery. Anesthesiology 1990;73:230-235.
15. Duke P, Maze M, Morrison P. Dexmedetomidine: a general overview. International Congress and Symposium Series Redefining Sedation 1998;221:11-22.
16. Whipple JK. Analysis of pain management in critically ill patients. Pharmacotherapy 1995;15:592-599.
17. Mantz J, Singer M. Importance of patient orientation and arousability as components of intensive care unit sedation. International Congress and Symposium Series Redefining Sedation 1998;221:23-29.
18. Shahbaz R, Arain MD, Thomas J. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002;95:461-466.